Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Ozempic, originally prescribed for type 2 diabetes, is now widely used off-label for weight loss, but rapid results can lead ...